Scarica l'app Stockscreener
24.58
0.00%
0.00
Dopo l'orario di chiusura:
24.60
0.02
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today - Yahoo Finance
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - Insider Monkey
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? - Nasdaq
Astrocytoma Market to See Strong Growth Through 2034 as Pfizer, - openPR.com
Pfizer workers taken to hospital for 'potential exposure to materials,' company says - WWMT
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Sponsored Content: Pfizer’s Anti-Counterfeit Lab - WTNH.com
Pfizer’s New Study on Zavicefta: A Potential Game-Changer for Sepsis and Renal Impairment - TipRanks
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Update for Investors - TipRanks
Flu Shot Season Puts Pfizer Back In Radio’s Ad Elite - Radio Ink
Pfizer launches next-gen vaccine for pneumococcal disease - The Economic Times
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results? - The Globe and Mail
Should Pfizer Stock Be In Your Portfolio After Solid Q2 Results? - Barchart.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded - simplywall.st
GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal - Law360
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - Seeking Alpha
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Pfizer’s Clinical Study on Drug Interactions in Obesity Treatment: Key Update - The Globe and Mail
CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlement - Endpoints News
Rx Rundown: Pfizer, SERB Pharmaceuticals, Novo Nordisk and more - Medical Marketing and Media
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - MSN
CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech - Reuters
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech - pharmaphorum
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study - TipRanks
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
Pfizer (PFE) Releases Financial Results for Q2 2025 - Insider Monkey
Pfizer’s MEVPRO-1 Study: A New Frontier in Prostate Cancer Treatment - TipRanks
Pfizer’s New Study on PF-07799544: A Potential Game-Changer in Cancer Treatment - TipRanks
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech - The Mighty 790 KFGO
Burn Pain Market: Epidemiology, Therapies, Companies, DelveInsight | Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Li - Barchart.com
Is Pfizer A Buy After Blowing Away Second-Quarter Views? - Investor's Business Daily
Pfizer’s New Breast Cancer Treatment Study: A Potential Game-Changer? - TipRanks
PFE’s Recent Struggles: A Market Perspective - StocksToTrade
Pfizer’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Promising Phase 1 Study on PF-07799933 for Advanced Solid Tumors - TipRanks
Pfizer’s ATGAM Study: A Closer Look at Safety in Aplastic Anemia Treatment - TipRanks
Pfizer’s Rimegepant Study: Assessing Safety in Pregnancy - TipRanks
Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma - TipRanks
Pfizer’s MAGNETISMM-6 Study: A New Horizon in Multiple Myeloma Treatment - TipRanks
Pfizer’s Latest Study on Enfortumab Vedotin: A Boost for Urothelial Cancer Treatment - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer for Maternal Health - TipRanks
Pfizer’s Promising Migraine Study: A Potential Game-Changer for Adolescents - TipRanks
Pfizer’s Somatrogon Study in India: A Key Update for Investors - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Prostate Cancer Study: A Potential Game-Changer - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for Infant RSV Protection - TipRanks
Pfizer’s Korean Surveillance Study: Ensuring Comirnaty’s Safety Post-Market - TipRanks
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Pfizer's Upcoming Earnings and Strategic Innovation in Biopharma: A Deep Dive into Value Potential - AInvest
United States Pharmaceutical Market Forecast and Company - GlobeNewswire
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Pfizer's Turnaround Has Truly Started (Earnings Update) - Seeking Alpha
Pfizer Romania recognized as a Best Place to Work for 2025 - TradingView
Jim Cramer Warns that Pfizer “Shareholder Base is Getting Very Restive” - Insider Monkey
Pfizer's Strategic Position in the Evolving Health Sector: Navigating Innovation and Regulatory Crosscurrents - AInvest
Pfizer Q2 2025 Earnings: Strong Growth Amid Challenges - The Globe and Mail
Pfizer's Innovation-Driven Turnaround and Its Implications for the Health Sector - AInvest
0.89%
1.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):